A naukri.com initiative
Bioengineer
6d
314
Image Credit: Bioengineer
Outcome Markers of Approved CD19 CAR T Cells
- CD19-targeted CAR T cell therapy has revolutionized cancer immunotherapy, particularly for large B cell lymphoma (LBCL), offering significant promise in tackling relapsed and refractory cases.
- FDA-approved CD19-directed CAR T cell products, such as axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), have shown impressive response rates but face challenges in long-term durability and relapse prevention.
- Toxicities like cytokine release syndrome (CRS) and neurotoxicity pose critical clinical concerns in CAR T cell therapy, necessitating close monitoring and intervention strategies.
- Research on predictive biomarkers and risk models aims to enhance patient management and guide interventions to mitigate treatment-related toxicities.
- Real-world data complements clinical trial findings, shedding light on broader patient outcomes, toxicity management, and treatment nuances.
- Ongoing efforts focus on optimizing CAR T cell constructs, addressing antigen escape, improving manufacturing processes, and personalizing therapy decisions to enhance efficacy and safety.
- The dynamic landscape of CAR T cell therapy necessitates continuous data collection, patient-centered approaches, and interdisciplinary collaborations to advance towards curative outcomes for LBCL patients.
- Challenges like disease relapse, toxicity management, and manufacturing complexities persist, driving the need for innovative solutions and refinements in CAR T cell therapy for LBCL.
- The evolving field of immunotherapy holds promise for overcoming current limitations, reshaping therapeutic horizons, and improving long-term survivorship in large B cell lymphoma cases worldwide.
Read Full Article
18 Likes
For uninterrupted reading, download the app